JMIR Medical Informatics
Clinical informatics, decision support for health professionals, electronic health records, and eHealth infrastructures.
Editor-in-Chief:
Arriel Benis, PhD, FIAHSI, SMIEEE, Associate Professor and Head of the Department of Digital Medical Technologies, Holon Institute of Technology (HIT), Israel
Impact Factor 3.8 More information about Impact Factor CiteScore 7.7 More information about CiteScore
Recent Articles


Severe COVID-19 is a global health concern despite continuous vaccination campaigns because current therapies, such as dexamethasone and remdesivir, do not considerably improve immune function, especially in high-risk individuals. SARS-CoV-2–specific T cells (CoV-2-STs) from vaccinated or convalescent donors are a promising new treatment that can enhance clinical outcomes and viral-specific immunity. CoV-2-STs improve T cell proliferation and recovery without raising safety concerns, according to randomized studies. Targeting patients for immunotherapy is made more difficult by the variability in COVID-19 progression brought on by variables like age and comorbidities. In order to further enable precision medicine and patient care, machine learning techniques are being used to analyze clinical data, predict disease severity, and optimize treatment. However, their use in guiding the treatment of novel therapies like CoV-2-STs using early cellular immunology data is limited and requires improvement.


Gastrointestinal (GI) cancers are a significant health concern in South Korea. Recently, machine learning (ML) models have emerged as powerful tools to support early screening efforts and identify people at risk before disease onset. However, the low incidence of GI malignancies in prospective cohorts leads to severe class imbalance, often causing ML models to favor the majority “healthy” class at the expense of clinical sensitivity.

Clinical note documentation is a vital yet time-intensive task in health care. While advancements in natural language processing have transformed many domains, generating accurate summaries of doctor-patient conversations remains underexplored due to the limited availability of open-source datasets. Large language models (LLMs), with their training on vast datasets, present a promising solution to this challenge.

Malnutrition in critically ill patients is associated with increased morbidity and mortality, yet traditional screening tools such as the modified NUTRIC (mNUTRIC) score often rely on subjective assessments or delayed data, limiting their utility for early intervention in the dynamic intensive care unit (ICU) environment. Real-time, data-driven approaches using electronic health records offer a promising solution for automated and objective risk stratification.

Severe trauma remains a leading cause of admission to the intensive care unit. The Trauma and Injury Severity Score (TRISS) is an established standard for predicting outcomes and benchmarking the quality of trauma care globally. However, the TRISS model has some limitations when used for benchmarking trauma care.

Clinical trial accrual monitoring is a critical component of trial operations, influencing feasibility, timeliness, and scientific validity. Despite its importance, many National Cancer Institute–designated cancer centers continue to rely on static spreadsheets or manually generated reports that provide delayed and incomplete insight for study teams. These limitations hinder timely identification of recruitment challenges, reduce transparency across stakeholders, and constrain proactive operational decision‑making. Scalable, institution‑wide systems that support near–real‑time accrual oversight remain uncommon in academic settings.

Depressive symptoms are linked to nutritional vulnerability and functional decline in aging populations, but their relationships with nutritional risk and lower-extremity physical performance are often examined separately. Tree-based exploratory approaches may provide transparent subgroup characterization.

There is significant potential for ambient scribe technology to enhance health care productivity, with a growing range of applications being developed and implemented internationally. Strong organizational drivers to improve efficiency, coupled with the technology’s potential to help address clinician burnout, are accelerating interest and adoption. However, limited attention has been paid to the integration of such systems within electronic health records and unintended consequences, as stakeholders navigate their implementation and integration into clinical practice.

Alzheimer disease (AD) is a progressive neurodegenerative disorder with rapidly growing global prevalence. Early detection is critical for timely intervention; yet, conventional diagnostic methods remain costly and invasive. Speech-based assessment has emerged as a noninvasive alternative, as AD characteristically impairs linguistic abilities including fluency, coherence, and informational content. Recent advances in large language models (LLMs) offer new opportunities to extract structured linguistic features from transcribed speech for automated AD classification. However, existing LLM-based approaches often lack transparency and clinical interpretability, limiting their adoption in clinical workflows.

Blockchain technologies have revolutionized the financial sector through their ability to generate immutable, cryptographically secure records. Clinical trials and health care data possess several synergies with those of the financial sector, specifically pertaining to the importance of tamper-resistant recording of processes. The evolution of blockchain to autonomously execute tasks contingent upon predefined contractual terms via smart contracts (SCs) allows a dynamic chain of interlinked events to unfold independently and in sequence, with time-stamped records. In recent years, mistrust in clinical trial data has grown significantly. Recording the entire clinical trial lifecycle from application, registration, recruitment to conduct, finance management, statistical analysis, and reporting in an immutable, cryptographically secure ledger with SC execution of trial processes could limit the potential for human intervention and tampering. This would produce a time-stamped record of all events within the trial lifecycle. Leveraging the capabilities of SCs could alleviate recruitment challenges and address ongoing concerns regarding data transparency, ownership, and integrity that currently undermine clinical trial processes.
Preprints Open for Peer Review
Open Peer Review Period:
-






